Motif Bio plc announces that its lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019.
2 September 2019
Motif Bio plc (“Motif Bio” or the “Company”)
Motif Bio and Hercules Capital Amend Loan and Security Agreement
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that its lender, Hercules Capital, Inc. (“Hercules”), has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019. This change means that the September payment will be interest only. Hercules made this change in support of Motif Bio managing its cash position to advance its pipeline expansion strategy and prepare for the upcoming meeting with the U.S. Food and Drug Administration.
Dr. Graham Lumsden, Chief Executive Officer, said: “We are well prepared for the meeting with the FDA on September 19 to discuss our proposed clinical trial for iclaprim. In addition, we are actively pursuing options to broaden our pipeline as we work to build shareholder value. We appreciate the continued support and flexibility of Hercules and the confidence that they have in our team to deliver on our strategic goals.”
For further information please contact:
Motif Bio plc | ir@motifbio.com |
Graham Lumsden (Chief Executive Officer) | |
Peel Hunt LLP (NOMAD & JOINT BROKER) | + 44 (0)20 7418 8900 |
Dr Christopher Golden | |
Oliver Jackson | |
SP Angel Corporate Finance LLP (JOINT BROKER) | +44 (0)20 3470 0470 |
David Hignell | |
Vadim Alexandre | |
Rob Rees |
Walbrook PR Ltd. (UK FINANCIAL PR & IR) | +44 (0)20 7933 8780 |
Paul McManus/Lianne Cawthorne | motifbio@walbrookpr.com |
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 |
Raimund Gabriel | raimund.gabriel@mc-services.eu |
LifeSci Advisors (U.S. IR) | +1 (646) 597 6989 |
Bob Yedid | bob@lifesciadvisors.com |